UPDATE: Rodman & Renshaw Raises PT to $16 on Omeros Corporation

Rodman & Renshaw increases its price target $3 to $16 on Outperform-rated Omeros Corporation OMER as pivotal eye data achieves all endpoints. Rodman & Renshaw says, "Today Omeros announced positive data from its Phase 3 clinical trial evaluating its combination drug OMS302 in patients undergoing intraocular lens replacement surgery. The study achieved its primary endpoint, which was the successful maintenance of pupil dilation (mydriasis) in intraocular lens replacement surgeries, coupled with reduction of postoperative pain (secondary endpoint)." OMER closed at $9.40 a share on Monday.